Business Context and Reporting Period
Company: Tempest Therapeutics, Inc. (TPST)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Tempest is a clinical-stage biotechnology company focused on developing targeted and immune-mediated oncology therapies. Its lead program, amezalpat (TPST-1120), is advancing toward a pivotal Phase 3 trial for first-line hepatocellular carcinoma (HCC). The company has no approved products and has not generated product revenue.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(10,556) | $(6,786) | $(28,030) | $(22,003) |
| Loss Per Share (Basic & Diluted) | $(0.41) | $(0.48) | $(1.19) | $(1.57) |
| Cash and Cash Equivalents (End of Period) | $22,116 | $11,506 | $22,116 | $11,506 |
| Operating Cash Flow (9 Months) | $(22,878) | $(21,182) | $(22,878) | $(21,182) |
| Total Debt (Current Portion) | $8,504 | $4,285 | $8,504 | $4,285 |
| Accumulated Deficit | $(193,293) | $(157,775) | $(193,293) | $(157,775) |
Note: Revenue is $0 as the company has not yet commercialized any products. Debt figures represent the current loan payable net of discounts and issuance costs.
Material Changes vs. Prior Period
- Increased Operating Expenses: Research and Development (R&D) expenses for the three months ended September 30, 2024, increased by 79% to $7.6 million compared to $4.2 million in the prior year period. This increase is primarily driven by costs associated with preparing for the pivotal Phase 3 trial of amezalpat.
- Stock-Based Compensation: Stock-based compensation expense rose significantly, totaling $3.97 million for the nine months ended September 30, 2024, compared to $1.45 million in the same period in 2023, reflecting increased headcount and equity grants.
- Debt Structure: The company began making monthly principal payments of $733,000 on its Oxford Finance loan starting July 1, 2024, following an interest-only period. The current loan balance increased to $8.5 million (net) from $4.3 million at the end of 2023 due to the reclassification of the remaining term loan to current liabilities as the maturity date approaches.
- Capital Raises: The company raised approximately $8.4 million net from its At-The-Market (ATM) offering program during the nine months ended September 30, 2024. Additionally, between October 1 and November 8, 2024, the company raised an additional $19.9 million net under the ATM program.
Guidance, Outlook, and Risks
- Clinical Progress: The FDA provided positive feedback on the Phase 3 trial design for amezalpat in first-line HCC. The company plans to advance TPST-1495 into a Phase 2 study for Familial Adenomatous Polyposis (FAP) in the second half of 2024.
- Liquidity Outlook: Management believes that existing cash of $22.1 million (as of Sept 30, 2024) combined with $19.9 million raised in October/November 2024 will fund operations for at least 12 months from the filing date. The company expects to incur significant losses in the foreseeable future.
- Financing Needs: The company will require substantial additional capital to fund clinical trials and operations. It intends to raise capital through equity or debt issuances, including its ATM program (with ~$196.4 million remaining capacity as of Sept 30, 2024), or strategic collaborations.
- Key Risks:
- Going Concern: The company has a history of losses and an accumulated deficit of $193.3 million. Continued operations depend on securing additional financing.
- Debt Covenants: The Oxford Finance loan is secured by a lien on all assets, including intellectual property, and contains covenants that could restrict operations if breached.
- Regulatory Uncertainty: Success depends on obtaining regulatory approval for product candidates, which is uncertain and costly.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $42 million total cash position (Sept 30 balance + Oct/Nov raises) against the projected burn rate for the upcoming Phase 3 trial.
- Debt Maturity: Confirm the terms of the Oxford Finance loan maturing August 1, 2025, and the company's ability to refinance or repay the $8.5 million principal.
- ATM Program Utilization: Monitor the pace of share sales under the ATM program and the potential for dilution to existing shareholders.
- Phase 3 Trial Initiation: Track the timeline for the initiation of the pivotal amezalpat Phase 3 trial and any associated cost escalations.
- Stock Price Volatility: Assess the impact of the company's "smaller reporting company" status and thin trading volume on liquidity and share price stability.